Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

Bibliography

• MICHELL RH et al: Hormonal stimulation of phosphati-dylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. (1979) 7:861–865.
   PubMedGoogle Scholar
• JARD S: Vasopressin isoreceptors in mammals: rela-tion to cyclic AMP-dependent and cyclic AMP-independent transduction mechanisms. In: Membrane Receptors. Kleinzeller A (Ed.), Academic Press, New York, UK (1983):255–285.
   Google Scholar
• THIBONNIER M: Cytoplasmic and nuclear signalling pathways of Vi-vascular vasopressin receptors. Regul Pept. (1993) 45:79–84.
   PubMed Web of Science ®Google Scholar
• THIBONNIER M et al: Signal transduction pathways of the human Vi-vascular, V2-renal, V3-pituitary AVP, and oxytocin receptors. Neuropeptides 1997 (In Press.)
   Google Scholar
• ANDREOLI TE: Edematous states: an overview. Kidney Intern. (1997) 51 (Suppl. 59):S2–S10.
   Google Scholar
• ANDERSON RJ et al: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med. (1985) 102:164–168.
   PubMed Web of Science ®Google Scholar
• ••Description of incidence, morbidity and mortality associatedto hyponatraemia.
   Google Scholar
• ALTURA BM, ALTURA BT: Vascular smooth muscle and neurohypophyseal hormones. Fed. Proc. (1977) 36:1853–1860.
   PubMedGoogle Scholar
• JOHNSTON CI: Vasopressin in circulatory control and hypertension. J. Hypertens. (1985) 3:557–569.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR: Vasopressin as vasopressor. Am. J. Med. (1987) 82:1213–1219.
   PubMed Web of Science ®Google Scholar
• AGUILERA G: Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. (1994) 15:321–350.
   PubMed Web of Science ®Google Scholar
• DAHIA PLM et al.: Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J. Endocrinol. Metab. (1996) 81:1768–1771.
   PubMed Web of Science ®Google Scholar
• DE KEYSER Y et al.: The pituitary V3 vasopressin recep-tor and the corticotroph phenotype in ectopic ACTH syndrome. J. Olin. Invest. (1996) 97:1311–1318.
   PubMed Web of Science ®Google Scholar
• FREIDINGER RM, PETTIBONE DJ: Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev. (1997) 17:1–16.
   PubMed Web of Science ®Google Scholar
• ••Review of oxytocin receptor antagonists in development.
   Google Scholar
• THIBONNIER M et al.: Structure of the human Via vaso-pressin receptor gene. In: Neurohypophysis: Recent Pro-gress of Vasopressin and Oxytocin Research. Saito T, Kurokawa K, Yoshida S (Eds.), Elsevier, Amsterdam, The Netherlands (1995):553–571.
   Google Scholar
• THIBONNIER M: Signal transduction of Vi-vascular va-sopressin receptors. Regul. Peptides (1992) 38:1–11.
   PubMed Web of Science ®Google Scholar
• BRILEY EM et al.: The cloned vasopressin Via receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels. Neuropeptides (1994) 27:63–74.
   PubMed Web of Science ®Google Scholar
• GEISTERFER AAT, OWENS GK: Arginine-vasopressin-induced hypertrophy of cultured rat aortic smooth muscle cells. Hypertension (1989) 14:413–420.
   PubMed Web of Science ®Google Scholar
• LUTZ W et al: Vasopressin receptor-mediated endocy-tosis in cells transfected with Vi- type vasopressin re-ceptors. Kidney Int. (1993) 43:845–852.
   PubMed Web of Science ®Google Scholar
• FISHMAN JB et al.: Internalization, recycling, and redis-tribution of vasopressin receptors in rat hepatocytes. J. Biol. Chem. (1985) 260:12641–12646.
   PubMed Web of Science ®Google Scholar
• NISHIOKA N et al: Wortmannin inhibits the activation of MAP kinase following vasopressin Vi receptor stimulation. FEBS Lett. (1995) 377:393–398.
   PubMed Web of Science ®Google Scholar
• GRANOT Y et al: Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen-activated protein kinase by vasopressin in cultured rat vascular smooth muscle cells. J. Biol. Chem. (1993) 268(13)9564–9569.
   Google Scholar
• BICHET DG et al: Nephrogenic diabetes insipidus due to mutations in AVPR2 and AQP2. In: Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Saito T, Kurokawa K, Yoshida S (Eds.) Elsevier, Amsterdam, The Netherlands (1995):605–613.
   Google Scholar
• ••Review of mutations of the V2 receptor and aquaporin 2leading to nephrogenic diabetes insipidus.
   Google Scholar
• HAYASHI M et al.: Expression and distribution of aqua- porin of collecting duct are regulated by vasopressin V2 receptor in rat kidney. J. Clin. Invest. (1994) 94:1778–1783.
   PubMed Web of Science ®Google Scholar
• KOJRO E, FAHRENHOLZ F: Ligand-induced cleavage of the V2 vasopressin receptor by a plasma membrane metalloproteinase. J. Biol. Chem. (1995) 270:6476–6481.
   PubMed Web of Science ®Google Scholar
• LOLAIT SJ et al.: Extrapituitary expression of the rat Vib vasopressin receptor gene. Proc. Natl. Acad. Sci. USA (1995) 92:6783–6787.
   PubMed Web of Science ®Google Scholar
• GRAZZINI E et al: Molecular and functional characteri-zation of Vib vasopressin receptor in rat adrenal me-dulla. Endocrinology (1996) 137:3906–3914.
   PubMed Web of Science ®Google Scholar
• DE KEYSER Y et al: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V3-pituitary vasopressin receptor. FEBS Lett. (1994) 356:215–220.
   PubMed Web of Science ®Google Scholar
• ANTONI F: Novel ligand specificity of pituitary vaso-pressin receptors in the rat. Neuroendocrinology (1984) 39:186–188.
   PubMed Web of Science ®Google Scholar
• BAERTSCHI AJ, FRIEDLI M: A novel type of vasopressin receptor on anterior pituitary corticotrophs? Endocri-nology (1985) 116:499–502.
   PubMed Web of Science ®Google Scholar
• GIGUERE V, LABRIE F: Vasopressin potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-release factor in rat anterior pituitary cells in culture. Endocrinology (1982) 111:1752–1754.
   PubMed Web of Science ®Google Scholar
• KNEPEL W et al.: In vitro adrenocortico-tropin/P-endorphin-releasing activity of vasopressin analogs is related neither to pressor nor to antidiuretic activity. Neuroendocrinology (1984) 38:344–350.
   PubMedGoogle Scholar
• LEVY A et al.: Inositol phospholipid turnover and intra-cellular Ca ++ responses to thyrotropin-releasing hor-mone, gonadotropin-releasing hormone and arginine vasopressin in pituitary corticotroph and somato-troph adenomas. Clin. Endocrinol. (1990) 33:73–79.
   PubMed Web of Science ®Google Scholar
• LIU JP: Studies of the mechanisms of action of corticotropin-releasing factor (CRF) and vasopressin (AVP) in the ovine anterior pituitary: evidence that CRF and AVP stimulate protein phosphorylation and dephosphorylation. Ma Cell. Endocrinol. (1994) 106:57–66.
   PubMed Web of Science ®Google Scholar
• LIU JP et al.: Arginine vasopressin (AVP) causes the re-versible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocortico-tropin (ACTH) secretion. Mol. Cell. Endocrinol. (1994) 105:217–226.
   PubMed Web of Science ®Google Scholar
• HOLMES MC, ANTONI FA, SZENTENDREI T: Pituitary re-ceptors for corticotropin-releasing factor: no effect of vasopressin on binding or activation of adenylate cy-clase. Neuroendocrinology (1984) 39:162–169.
   PubMed Web of Science ®Google Scholar
• JARD S etal: Vasopressin antagonists allow demonstra-tion of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol (1986) 30:171–177.
   PubMed Web of Science ®Google Scholar
• ARSENIJEVIC Y et al.: Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual re-ceptor subtype in the anterior lobe. J. Endocrinol (1994) 141:383–391.
   PubMed Web of Science ®Google Scholar
• THIBONNIER M et al.: The human V3-pituitary receptor:ligand-binding profile and density-dependent signal-ing pathways. Endocrinology (1997) 138:4109–4122.
   PubMed Web of Science ®Google Scholar
• •Study of the signal transduction pathways linked to the V3-p-ituitary receptor.
   Google Scholar
• KIMURA T, SAJI F: Molecular endocrinology of the oxy- tocin receptor. Endocrine J. (1995) 42:607–615.
   PubMed Web of Science ®Google Scholar
• •Study of the signal transduction pathways linked to oxytocin receptor.
   Google Scholar
• OHMICHI M et al.: Oxytocin stimulates mitogen-activated protein kinase activity in cultured human puerperal uterine myometrial cells. Endocrinology (1995) 136:2082–2087.
   PubMed Web of Science ®Google Scholar
• PHANEUF S et al.: Multiple G-proteins and phospholi-pase C isoforms in human myometrial cells: implica-tion for oxytocin action. J. Clin. Endocrinol. Metab. (1996) 81:2098–2103.
   PubMed Web of Science ®Google Scholar
• MANNING M et al.: Novel potent and selective antago-nists and radioiodinated ligands for oxytocin and va-sopressin receptors. In: Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Saito T, Kurokawa, Yoshida S, (Eds.), Elsevier, Amsterdam, The Netherlands (1995):21–38.
   Google Scholar
• ••Review of the development of peptide analogues. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(5)
   Google Scholar
• MANNING M, SAWYER WH: Antagonists of vasopressin and oxytocin: current status and future perspectives. In: Vasopressin. Jamison SJR (Ed.), John Libbey, Paris, Lon-don (1990:297–310.
   Google Scholar
• BUSSIEN JP et al: Does vasopressin sustain blood pres-sure of normally hydrated healthy volunteers? Am. J. Physiol (1984) 246:H143–H147.
   Google Scholar
• WAEBER B et al.: Clinical studies with a vascular vaso-pressin antagonist. J. Cardiovasc. Pharmacol. (1986) 8\(Suppl. 7):S111–5116.
   Google Scholar
• PAPADOLIOPOULOU-DIAMANDOPOULOU N et al.: Vaso-pressin in end-stage renal disease: relationship to salt, catecholamines and renin activity. Clin. Exp. Theory Pract. (1987) A9:1197–1208.
   Google Scholar
• RIBEIRO A: Sequential elimination of pressor mecha-nisms in severe hypertension in humans. Hypertension (1986) 8(Suppl. ID:1169–1173.
   Google Scholar
• RIBEIRO AB et al.: Vasopressin maintains blood pres-sure in diabetic orthostatic hypotension. Hypertension (1988) 11 (Suppl. 0:1-217-1-221.
   Google Scholar
• DE PAULA RB et al.: Age and race determine vasopressin participation in upright blood pressure control in es-sential hypertension. Ann. NY Acad. Sci. USA (1993) 689:534–536.
   PubMed Web of Science ®Google Scholar
• KINTER LB, CALTABIANO S, HUFFMAN WF: Anomalous antidiuretic activity of antidiuretic hormone antago-nists. Biochem. Pharmacol (1993) 45:1731–1737.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y et al.: OPC-21268, an orally effective non-peptide vasopressin Vi receptor antagonist. Science (1991) 252:572–574.
   PubMed Web of Science ®Google Scholar
• PHILLIPS PA et al.: Vasopressin antagonism; physiologi-cal and pharmacological roles. In: Neurohypophysis: Re-cent Progress of Vasopressin and Oxytocin Research. Saito T, Kurokawa K, Yoshida S (Eds.), Elsevier, Amsterdam (1995):643–658.
   Google Scholar
• ••Experience with non-peptide vasopressin antagonists.
   Google Scholar
• BURRELL LM et al.: Blood pressure lowering effect of an orally active vasopressin Vi receptor antagonist in mineralocorticoid hypertension in the rat. Hyperten-sion (1994) 23:737–743.
   PubMed Web of Science ®Google Scholar
• NAITOH M et al: Effects of oral AVP receptor antago-nists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. (1994) 267:H2245–H2254.
   Google Scholar
• BURRELL LM et al.: Vascular responses to vasopressin antagonists in man and rat. Clin. Sci. (1994) 87:389–395.
   PubMed Web of Science ®Google Scholar
• SERRADEIL-LE GAL C et al.: Effect of a new potent, non-peptide Via vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on swiss 3T3 cells. Biochem. Pharmacol. (1994) 47:633–641.
   PubMed Web of Science ®Google Scholar
• SERRADEIL-LE GAL C et al.: Biochemical and pharmacol-ogical properties of 5R49059, a new potent, non-peptide antagonist of rat and human vasopressin Via receptors. J. Clin. Invest. (1993) 92:224–231.
   PubMed Web of Science ®Google Scholar
• •Characteristics of the non-peptide V1 antagonist SR 49059.
   Google Scholar
• SERRADEIL-LE GAL C et al: Effect of SR-49059, a vaso-pressin Via antagonist, on human vascular smooth muscle cells. Am. J. Physiol (1995) 37:H404–H410.
   Google Scholar
• SERRADEIL-LE GAL C et al: Effects of SR 49059, a non-peptide antagonist of vasopressin Via receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits. Fundam. Gun. Pharmacol (1995) 9:17–24.
   PubMed Web of Science ®Google Scholar
• BROUARD R, CHASSARD D, HEDIARD N: The advantagesof surrogate markers during Phase I for new explora-tory compounds. Application for AR 49059, an orally active Via vasopressin receptor antagonist. Thérapie (1995). 4:S34.
   Google Scholar
• WEBER R et al.: Effects of SR-49059, a new orally active and specific vasopressin Vi receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hy-pertension (1997) 30:1121–1127.
   PubMed Web of Science ®Google Scholar
• BOSSMAR T et al: Effects of SR 49059, an orally active Via vasopressin receptor antagonist, on vasopressin-induced uterine contractions. Br. J. Obste1 Gynaecol (1997) 104:471–477.
   Google Scholar
• WU WX et al.: Characterization of oxytocin receptor ex-pression and distribution in the pregnant sheep uterus. Endocrinology (1996) 137(2)722–728.
   Google Scholar
• KITIYAKARA C, WILCOX CS: Vasopressin V2-receptor antagonists: panaceas for hyponatremia? Curr. Opin. Nephrol. Hypertens. (1997) 6:461–467.
   PubMed Web of Science ®Google Scholar
• SAITO T et al.: Acute aquaresis by the nonpeptide ar-ginine vasopressin (AVP) antagonist OPC-31260 im-proves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SI-ADID. J. Clin. Endocrinol. Metabol (1997) 82:1054–1057.
   PubMed Web of Science ®Google Scholar
• CHAN PS et al. Aquaretic effects of VPA-985, a potentorally active nonpeptide AVP V2 receptor antagonist. 1997 World Congress of NeurohypophysialHormones. Mon-tréal, Canada (1997).
   Google Scholar
• LAI F et al. Effects of the vasopressin V2 antagonist VPA-985 in rat caudal arteries and on arterial pressure in normotensive, SHR, and DOCA-salt hypertensive rats. 1997 World Congress of Neurohypophysial Hormones. Montréal, Canada (1997)
   Google Scholar
• ABRAHAM WT, OREN RM, SCHRIER RW: Effects of anoral nonpepide, selective V2 receptor antagonist in hu-man heart failure. 1997 World Congress of Neurohypo-physial Hormones. Montréal, Canada (1997).
   Google Scholar
• SERRADEIL-LE GAL C et al.: Characterization of SR-121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. (1996) 98:2729–2738.
   PubMed Web of Science ®Google Scholar
• SLADEK CD, BLAIR MI, MANGIAPANE M: Evidence against a pressor role for vasopressin in spontaneous hypertension. Hypertension (1987) 9:332–338.
   PubMed Web of Science ®Google Scholar
• SLADEK C et al.: Attenuation of spontaneous hyperten-sion in rats by a vasopressin antagonist. Hypertension (1988) 12:506-512. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(5)
   Google Scholar
• HOFBAUER K et al: Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hyper-tension. J. Cardiovasc. Pharmacol (1984) 6:S184–S191.
   PubMed Web of Science ®Google Scholar
• TAHARA A et al: Pharmacological profile of YM087, a novel potent nonpeptide vasopressin Via and V2 re-ceptor antagonist, in vitro and in vivo. J. Pharmacol Exp. Ther. (1997) 282:301–308.
   PubMed Web of Science ®Google Scholar
• FRICKER AF, BURNIER M, BRUNNER HR: Evaluation of the non-peptide. orally active, Vi /V2 receptor antago-nist YM087 in normal subjects. 1997 World Congress of Neurohypophysial Hormones. Montréal, Canada (1997). Marc Thibonnier
   Google Scholar